^
    Back
    Association details:
    Biomarker:HER-2 amplification + HER-2 L755S
    Cancer:HER2 Positive Breast Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant

    Published date:
    10/14/2021
    Excerpt:
    A 48-year woman diagnosed with HER2-positive LABC...results discovered L755S in ERBB2 gene. Then, she received effective treatment with pyrotinib plus capecitabine and underwent mastectomy after six cycles of combined treatment with PR...In conclusion, pyrotinib is a potential neoadjuvant agent for patients who are heavily pretreated and harbor both ERBB2 amplification and ERBB2 mutant in locally advanced breast cancer.
    Secondary therapy:
    capecitabine
    DOI:
    https://doi.org/10.3389/fonc.2021.715554